{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:05:07Z","timestamp":1768874707876,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s12094-020-02288-9","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T17:06:04Z","timestamp":1581440764000},"page":"1517-1523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-0200","authenticated-orcid":false,"given":"J.-F. M.","family":"Jos\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Silverio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Federico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Isabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.-A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Inmaculada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cristina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-C.","family":"Julia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. M.","family":"Dolores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Jose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Paola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"del P.","family":"Nieves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vicent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Sara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Juli\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Manuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"del Carmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. M.","family":"\u00c1ngel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"issue":"1","key":"2288_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"370","key":"2288_CR2","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"22","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;22(370):2103\u201311.","journal-title":"Lancet"},{"issue":"2","key":"2288_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2011","unstructured":"Motzer RJ, Hutson TE, Tomczack P, Michaelson MD, Bukowski RM, et al. Sunitinib versus interfer\u00f3n alfa in metastatic renal-cell carcinoma. N Engl J Med. 2011;356(2):115\u201324.","journal-title":"N Engl J Med"},{"issue":"6","key":"2288_CR4","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2288_CR5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331.","journal-title":"N Engl J Med"},{"issue":"9807","key":"2288_CR6","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931\u20139.","journal-title":"Lancet"},{"issue":"9637","key":"2288_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449\u201356.","journal-title":"Lancet"},{"issue":"19","key":"2288_CR8","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al. Nivolumab versus everolimus in renal cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"key":"2288_CR9","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"19","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma. N Engl J Med. 2015;19:1814\u201323.","journal-title":"N Engl J Med"},{"key":"2288_CR10","first-page":"932","volume":"72","author":"B Escudier","year":"2017","unstructured":"Escudier B, Sharma P, McDermott D, George S, Hammers H, et al. Checkmate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017;72:932\u201371.","journal-title":"Eur Urol"},{"issue":"1","key":"2288_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bju.14461","volume":"123","author":"U De Giorgi","year":"2019","unstructured":"De Giorgi U, Carteni G, Giannarelli D, Basso U, Galli L, et al. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-word results from and expanded access program). BJU Int. 2019;123(1):98\u2013105.","journal-title":"BJU Int"},{"key":"2288_CR12","first-page":"5","volume":"37","author":"L Albiges","year":"2018","unstructured":"Albiges L, Negrier S, Dalban C, et al. Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC) Results from the NIVOREN GETUG-AFU 26 study. J Clin Oncol. 2018;37:5.","journal-title":"J Clin Oncol"},{"key":"2288_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12032-017-1002-6","volume":"34","author":"C Nieder","year":"2017","unstructured":"Nieder C, Syed MA, Dalhaugh A, Pawinski A, Norum J. Elegibility for a phase 3 clinical trials os systemic therapy in real-word patients with metastatic renal cell cancer managed in a rural region. Med Oncol. 2017;34:9.","journal-title":"Med Oncol"},{"key":"2288_CR14","first-page":"6","volume":"35","author":"S Yip","year":"2017","unstructured":"Yip S, Wells C, Moreira RB, Wong A, Srinivas S, et al. Real word experience of immune-oncology agents in metastatic renal cell carcinoma Results from the IMDC. J Clin Oncol. 2017;35:6.","journal-title":"J Clin Oncol"},{"key":"2288_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jgo.2018.07.015","volume":"10","author":"J Sattar","year":"2018","unstructured":"Sattar J, Kartolo A, Hopman WM, Lakoff JM, Baetz T. The efficacy and toxicity of immune checkpoint inhibitors in a real-word older patient population. J Geriatr Oncol. 2018;10:411\u20134.","journal-title":"J Geriatr Oncol"},{"issue":"Supplement","key":"2288_CR16","first-page":"1","volume":"41","author":"M Grimm","year":"2018","unstructured":"Grimm M, Gr\u00fcnwald V, Bedke J. Real world evidence in renal cell carcinoma: a national, prospective, non-interventional study of nivolumab in patients with advanced renal cell carcinoma after prior therapy (NORA). Oncol Res Treat. 2018;41(Supplement):1.","journal-title":"Oncol Res Treat"},{"issue":"3","key":"2288_CR17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.eururo.2017.03.037","volume":"72","author":"B Escudier","year":"2017","unstructured":"Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in Checkmate 025. Eur Urol. 2017;72(3):368\u201376.","journal-title":"Eur Urol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02288-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-020-02288-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02288-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T06:34:52Z","timestamp":1612938892000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-020-02288-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["2288"],"URL":"https:\/\/doi.org\/10.1007\/s12094-020-02288-9","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]},"assertion":[{"value":"31 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No organization has sponsored the research. The authors do not present a continuous financial relationship with the laboratory responsible for the drug referred to in the article. However, some of them have declared they have received fees for specific and punctual local talks (Dr Climent, Dra Marin, Dra Chirivella, Dr Sureda, Dr Ros, and Dr Juan).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has been approved by the appropriate ethics committee and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All alive persons gave their informed consent prior to their inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}